Clinical Trial Detail

NCT ID NCT02689284
Title Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors MacroGenics
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Margetuximab + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST